<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312436857</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312436857</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Matrix metalloproteinase-2 functional promoter polymorphism G1575A is associated with elevated circulatory MMP-2 levels and increased risk of cardiovascular disease in systemic lupus erythematosus patients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Bahrehmand</surname><given-names>F</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312436857">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Vaisi-Raygani</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312436857">1</xref>
<xref ref-type="aff" rid="aff2-0961203312436857">2</xref>
<xref ref-type="aff" rid="aff3-0961203312436857">3</xref>
<xref ref-type="corresp" rid="corresp1-0961203312436857"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Kiani</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff4-0961203312436857">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rahimi</surname><given-names>Z</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312436857">3</xref>
<xref ref-type="aff" rid="aff5-0961203312436857">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tavilani</surname><given-names>H</given-names></name>
<xref ref-type="aff" rid="aff6-0961203312436857">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Navabi</surname><given-names>SJ</given-names></name>
<xref ref-type="aff" rid="aff7-0961203312436857">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shakiba</surname><given-names>E</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312436857">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hassanzadeh</surname><given-names>N</given-names></name>
<xref ref-type="aff" rid="aff6-0961203312436857">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pourmotabbed</surname><given-names>T</given-names></name>
<xref ref-type="aff" rid="aff8-0961203312436857">8</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203312436857"><label>1</label>Molecular Diagnostic Research Center, Kermanshah University of Medical Sciences, Iran</aff>
<aff id="aff2-0961203312436857"><label>2</label>Fertility and Infertility Research Center, Kermanshah University of Medical Sciences, Iran</aff>
<aff id="aff3-0961203312436857"><label>3</label>Department of Clinical Biochemistry, Kermanshah University of Medical Sciences, Iran</aff>
<aff id="aff4-0961203312436857"><label>4</label>Department of Pharmacology and toxicology, Shahid Behshti, University of Medical Sciences, Tehran, Iran</aff>
<aff id="aff5-0961203312436857"><label>5</label>Medical Biology Research Center, Kermanshah University of Medical Sciences, Iran</aff>
<aff id="aff6-0961203312436857"><label>6</label>Department of Clinical Biochemistry, Hamadan University of Medical Sciences, Iran</aff>
<aff id="aff7-0961203312436857"><label>7</label>Department of Internal Medicine, Kermanshah University of Medical Sciences, Iran</aff>
<aff id="aff8-0961203312436857"><label>8</label>Department of Microbiology, Immunology and Biochemistry, University of Tennessee, Health Science Center, USA</aff>
<author-notes>
<corresp id="corresp1-0961203312436857">A Vaisi-Raygani, Department of Clinical Biochemistry, School of Medicine, Kermanshah University of Medical Sciences, Daneshgah Avenue, PO Box 6714869914 Kermanshah, Iran Email: <email>asadvaisiraygani@kums.ac.ir</email> and <email>avaisiraygani@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>21</volume>
<issue>6</issue>
<fpage>616</fpage>
<lpage>624</lpage>
<history>
<date date-type="received"><day>9</day><month>8</month><year>2011</year></date>
<date date-type="accepted"><day>30</day><month>12</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Matrix metalloproteinase-2 (MMP-2) is a zinc dependent endonuclease that degrades type IV collagen, the major structural component of basement membranes. MMP-2 functional promoter polymorphism G1575A affects circulating level of MMP-2 and may be considered an important genetic determinant of cardiovascular disease (CVD) in systemic lupus erythematosus (SLE) patients. In this study, association between MMP-2 1575A allele with serum MMP-2, neopterin and lipid-lipoprotein levels and with SLE and developing CVD was investigated.</p>
<p>The present case–control study consisted of 109 SLE patients with and without CVD (mean age, 35.6 years) and 101 gender- and age-matched, unrelated, healthy controls (mean age, 37.1 years) from the population in the west of Iran. MMP-2 1575G/A polymorphism was detected by polymerase chain reaction (restriction fragment length polymorphism) PCR-RFLP, serum MMP-2, neopterin and lipid levels were determined by enzyme-linked immunosorbent assay (ELISA), high-performance liquid chromatography (HPLC) and enzyme assay, respectively.</p>
<p>The presence of MMP-2 G1575A allele was found to be associated with SLE and developed CVD (OR = 1.78, <italic>p</italic> = 0.029 and OR = 3.43, <italic>p</italic> = 0.025, respectively). The SLE patients with MMP-2 A (G/A + A/A) allele had higher MMP-2 activity (301 ± 166 vs. 194 ± 35.5, <italic>p</italic> = 0.002), neopterin (29.4 ± 39.4 vs. 7.3 ± 4.6, <italic>p</italic> = 0.005), LDL-C (120 ± 25.7 vs. 87 ± 39.3, <italic>p</italic> = 0.045) and lower HDL-C (39.6 ± 11 vs. 45.9 ± 11.8, <italic>p</italic> = 0.031) levels than the control subjects. There was a significantly positive correlation between MMP-2 level with neopterin, total cholesterol and TG levels and negative correlation with HDL-C level in SLE patients with CVD.</p>
<p>MMP-2 G1575A allele may be a risk factor for SLE. The carriers of this allele have high levels of MMP-2, neopterin, total cholesterol and TG and lower levels of HDL, thus, they are more likely to develop heart disease.</p>
</abstract>
<kwd-group>
<kwd>Cardiovascular disease</kwd>
<kwd>matrix metalloproteinase-2</kwd>
<kwd>MMP-2 concentration</kwd>
<kwd>neopterin</kwd>
<kwd>genetic polymorphism</kwd>
<kwd>lipid profile</kwd>
<kwd>lupus nephropathy</kwd>
<kwd>blood pressure</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312436857" sec-type="intro"><title>Introduction</title>
<p>Coronary heart disease and stroke have been reported as one of the main causes of death in the patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).<sup><xref ref-type="bibr" rid="bibr1-0961203312436857">1</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr3-0961203312436857">3</xref></sup> SLE is an inflammatory autoimmune disease that can affect any organs, including skin, joints, kidneys, blood cells, and nervous system. It is characterized by an autoantibody response to nuclear and cytoplasmic antigens.<sup><xref ref-type="bibr" rid="bibr4-0961203312436857">4</xref>,<xref ref-type="bibr" rid="bibr5-0961203312436857">5</xref></sup> Cardiovascular diseases are the most frequent underlying cause of death in SLE patients.<sup><xref ref-type="bibr" rid="bibr6-0961203312436857">6</xref></sup></p>
<p>A multicenter study demonstrated that SLE patients had a 4.6-fold increased mortality rate compared with the general population; 25% of the deaths were caused by cardiovascular disease.<sup><xref ref-type="bibr" rid="bibr7-0961203312436857">7</xref>,<xref ref-type="bibr" rid="bibr8-0961203312436857">8</xref></sup> Therefore, early detection of susceptibility of patients with SLE to cardiovascular disease is of significant value.</p>
<p>MMPs are a family of zinc-dependent enzymes that collectively degrade all of the components of the connective tissue including collagen types I–V, fibronectin, laminin, elastin and proteoglycans.<sup><xref ref-type="bibr" rid="bibr9-0961203312436857">9</xref>,<xref ref-type="bibr" rid="bibr10-0961203312436857">10</xref></sup> It has been reported that some of the MMP gene polymorphisms such as MMP-2 1575A are associated with susceptibility to cardiovascular disease.<sup><xref ref-type="bibr" rid="bibr6-0961203312436857">6</xref>,<xref ref-type="bibr" rid="bibr11-0961203312436857">11</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr13-0961203312436857">13</xref></sup> MMP-2, also known as gelatinase A or 72-kDa type IV collagenase, that is secreted from macrophages in fibrous caps, has been suggested to be involved in the remodeling processes associated with atherosclerosis and plaque rupture and play important roles in the development of rheumatic diseases including SLE.<sup><xref ref-type="bibr" rid="bibr10-0961203312436857">10</xref>,<xref ref-type="bibr" rid="bibr11-0961203312436857">11</xref>,<xref ref-type="bibr" rid="bibr13-0961203312436857">13</xref>,<xref ref-type="bibr" rid="bibr14-0961203312436857">14</xref></sup> Genetic studies have shown that functional promoter variations of the <italic>MMP-2</italic> gene are associated with cardiovascular disease (CVD) and SLE.<sup><xref ref-type="bibr" rid="bibr8-0961203312436857">8</xref>,<xref ref-type="bibr" rid="bibr12-0961203312436857">12</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr15-0961203312436857">15</xref></sup> The G to A single nucleotide polymorphism at position -1575 in the promoter region of the <italic>MMP-2</italic> gene is found to be associated with coronary artery disease and SLE.<sup><xref ref-type="bibr" rid="bibr8-0961203312436857">8</xref>,<xref ref-type="bibr" rid="bibr12-0961203312436857">12</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr17-0961203312436857">17</xref></sup></p>
<p>The role of MMP-2 in heart disease (HD) and SLE have been substantiated by genetic studies showing that functional promoter variations of the <italic>MMP-2</italic> gene are related to presence and HD and SLE.<sup><xref ref-type="bibr" rid="bibr8-0961203312436857">8</xref>,<xref ref-type="bibr" rid="bibr12-0961203312436857">12</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr15-0961203312436857">15</xref></sup> Several reports have identified several single nucleotide polymorphisms in the <italic>MMP-2</italic> gene including the G to A transition at position −1575 in the promoter region of the protein.<sup><xref ref-type="bibr" rid="bibr8-0961203312436857">8</xref>,<xref ref-type="bibr" rid="bibr16-0961203312436857">16</xref></sup> The 1562A allele has a higher promoter for transcription of MMP-2 and is associated with coronary heart disease and SLE.<sup><xref ref-type="bibr" rid="bibr8-0961203312436857">8</xref>,<xref ref-type="bibr" rid="bibr12-0961203312436857">12</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr17-0961203312436857">17</xref></sup> This is a common polymorphism in the promoter region of human <italic>MMP-2</italic> gene.</p>
<p>MMP-2 is highly up-regulated in atherosclerotic plaques of coronary arteries<sup><xref ref-type="bibr" rid="bibr18-0961203312436857">18</xref></sup> and plasma MMP-2 levels are positively correlated with LDL-cholesterol levels in patients with premature coronary atherosclerosis.<sup><xref ref-type="bibr" rid="bibr19-0961203312436857">19</xref></sup> Plasma levels of MMP-2 are shown to increase gradually after the onset of acute myocardial infarction with maximum elevation on day 21 after onset.<sup><xref ref-type="bibr" rid="bibr20-0961203312436857">20</xref></sup></p>
<p>To our knowledge, there are no published data regarding the relationship between MMP-2 G1575A polymorphism, plasma level of MMP-2 and the risk of CVD in SLE patients.</p>
<p>The aim of the present study was to investigate whether MMP-2 G1575A promoter gene polymorphism has any effect on the plasma MMP-2 level, lipid profile, the level of neoptrin and consequently on the development of the CVD, hypertension and lupus nephritis in patients with SLE in the population of western Iran.</p></sec>
<sec id="sec2-0961203312436857" sec-type="materials|methods"><title>Materials and methods</title>
<sec id="sec3-0961203312436857" sec-type="subjects"><title>Subjects</title>
<p>A total of 109 SLE patients (mean age, 37.3 ± 11.3 years; range, 15–75 years; 87 females and 22 males) were recruited through the Rheumatology Division of the Imam Reza Hospital of the Kermanshah University of Medical Science. The diagnosis of SLE in patients was based on at least four of the criteria set for diagnosis of SLE by the American College of Rheumatology (ACR).<sup><xref ref-type="bibr" rid="bibr21-0961203312436857">21</xref></sup></p>
<p>Clinical and laboratory findings were defined using ACR criteria and collected from well-documented medical records during the follow-up. The SLICC/ACR Damage Index was calculated at the time of blood sampling.<sup><xref ref-type="bibr" rid="bibr22-0961203312436857">22</xref></sup></p>
<p>Clinical findings were collected including age, gender, involved organs, duration and severity of the disease. Examination, including chest X-ray, electrocardiogram, ultrasonic cardiogram, neurological examination, urine analysis, brain computed tomography scan or magnetic resonance imaging were performed for detection of cardiovascular and renal involvement. Hypertension was defined as resting systolic blood pressure ≥ 160 mmHg and diastolic blood pressure ≥ 95 mmHg. Lupus nephropathy was defined as SLE patients with a history of proteinuria greater than 500 mg/day or when renal biopsy had a diffuse or focal proliferative lesion.</p>
<p>The control subjects (mean age, 37.1 ± 11.5 years; range, 15–72 years; 82 females and 22 males) were selected from healthy individuals during their annual checkup at the Hospitals of the Kermanshah University of Medical Science. The patient and control groups were matched according to gender, age, and race. All healthy donors were interviewed and examined for coronary heart disease, RA and SLE and did not have any specific diseases at their annual medical checkup. Individuals with a history of cardiovascular diseases, hypertension, autoimmune diseases or with family history of any of the above diseases were excluded from the study. The study protocol was approved by the Ethics Committee of the Kermanshah University of Medical Sciences and was in accordance with the principles of the Declaration of Helsinki II and all subjects provided written informed consent.</p></sec>
<sec id="sec4-0961203312436857"><title>Chemical analysis</title>
<sec id="sec5-0961203312436857"><title>Measurement of serum MMP-2 levels</title>
<p>Concentration of MMP-2 in serum was measured by quantitative sandwich enzyme immunoassay technique (Quantikine UK) according to the manufacturer’s instructions.</p></sec>
<sec id="sec6-0961203312436857"><title>Neopterin</title>
<p>Neopterin, methanol, acetonitrile and diammonium hydrogen phosphate were analytical grade and purchased from Sigma Chemical Co. (St Louis, MO, USA), all other reagents were products from Merck (Darmstadt, Germany).</p>
<p>The amount of Neopterin in the serum samples was quantitated by HPLC procedure as described.<sup><xref ref-type="bibr" rid="bibr23-0961203312436857">23</xref>,<xref ref-type="bibr" rid="bibr24-0961203312436857">24</xref></sup> Serum proteins were precipitated by 60% acetonitrile. The supernatant was dried by nitrogen gas steam at 37°C. The precipitate was dissolved in HCl (0.1 N) and applied to EC 250/4.6 Nucleodur 100-5 C18ec reverse phase HPLC column (Macherey-Nagel, Duren, Germany). Neopterin was eluted isocratically at a flow rate of 1 mL/min with 20% methanol in 80% ammonium phosphate, pH 6.0. Peaks were detected by monitoring fluorescence intensity of the effluent using excitation and emission wavelength at 353 and 438 nm, respectively. The amount of neopterin was determined using a commercial neopterin as external standard and quantified by peak area using Agilent Technologies 1200 Series software. All analysis was conducted in duplicate and data was displayed as the mean ± the standard error of the mean of duplicate treatments.</p></sec>
<sec id="sec7-0961203312436857"><title>Serum lipids</title>
<p>Total serum cholesterol (TC), triacylglycerol (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels were measured by the standard enzymatic method (Pars Azmon kit, Iran), using an automated Erba XL-600 (Mannheim, Germany).</p></sec>
<sec id="sec8-0961203312436857"><title>DNA analysis</title>
<p>Genomic DNA was extracted from peripheral blood leukocytes using phenol chloroform extraction method.<sup><xref ref-type="bibr" rid="bibr25-0961203312436857">25</xref></sup> Genotyping of all individuals was done without knowledge of their groups or disease. The MMP-2 nucleotide polymorphism at position 1575 was determined by PCR using 5'-CACACCCACCAGACAAGCCT-3' and 5'-TGGGGAATATGGGGAATGTT-3' as the forward and reverse primers, respectively.<sup><xref ref-type="bibr" rid="bibr26-0961203312436857">26</xref></sup> The PCR amplification reaction contained 50–100 ng genomic DNA, 10 pmol of each primer, 200 µM of each dNTP, 0.5 U Taq DNA polymerase in Taq DNA reaction buffer. After the DNA was denatured at 95°C for 5 min, the reaction mixture was subjected to 35 cycles of 94°C for 1.0 min, 58.2°C for 1.0 min and 72°C for 1.5 min with a final extension time of 10 min. PCR products were digested with RcaI (PagI) restriction endonuclease at 37°C for 5 h and the digested products were separated on a 2.5% agarose gel and visualized by ethidium bromide staining. The PCR product of −1575G (349 bp) allele is not cleaved by RcaI, while that of the −1575A allele is cleaved by the enzyme generating 260 and 89 bp fragments and heterozygotes of −1575G and A alleles are cleaved by the enzyme producing 349, 260 and 89 bp fragments (<xref ref-type="fig" rid="fig1-0961203312436857">Figure 1</xref>).
<fig id="fig1-0961203312436857" position="float"><label>Figure 1</label><caption><p>MMP-2 C-1562T polymorphism using the PCR-RFLP products were digested with RcaI restriction endonuclease and subjected to electrophoresis on a 3% agarose gel. Lane 1 G/A, lane 2 G/G; lane 3 G/A; lane 4 molecular marker; lane 5: PCR product; lanes 6 and 7, G/A. MMP: matrix metalloproteinase; PCR-RFLP: polymerase chain reaction (restriction fragment length polymorphism).</p></caption><graphic xlink:href="10.1177_0961203312436857-fig1.tif"/></fig></p></sec></sec>
<sec id="sec9-0961203312436857"><title>Statistical analysis</title>
<p>The allelic frequencies were calculated by the gene counting method. The χ<sup>2</sup> test was used to verify the agreement of the observed genotype frequencies with those expected according to the Hardy–Weinberg equilibrium. The genotypes and MMP-2 allele frequencies in SLE patients with CVD and high blood pressure were compared with those without CVD and high blood pressure using χ<sup>2</sup> test. Odds ratios (OR) were calculated as estimates of relative risk for disease and 95% confidence intervals obtained by SPSS logistic regression. The correlation values of plasma MMP-2 concentration, HDL-C, LDL-C, TC, TG and neoptrin levels with the MMP-2 polymorphism between the two groups were calculated using linear regression and an unpaired <italic>t</italic>-test. A two-tailed Student’s <italic>t</italic>-test, analysis of variance (ANOVA) and a non-parametric two independent sample Mann–Whitney analysis were used to compare quantitative data. Statistical significance was assumed at <italic>p</italic> &lt; 0.05.</p></sec></sec>
<sec id="sec10-0961203312436857" sec-type="results"><title>Results</title>
<p>The clinical and laboratory features of the patient and control groups are reported in <xref ref-type="table" rid="table1-0961203312436857">Table 1</xref>. The mean of age and gender distribution were the same in SLE patients and controls. Each of the lipid variables except for HDL-C and TG were significantly higher in SLE patients compared with the control group. The level of serum MMP-2 and neopterin were significantly higher in SLE patients than those in the control group (295 ± 141.5 vs. 188.1 ± 28.6 ng/mL, <italic>p</italic> &lt; 0.001) and (25.8 ± 38.1 vs. 6.5 ± 2.9 nmol/L, <italic>p</italic> &lt; 0.001), respectively (<xref ref-type="fig" rid="fig2-0961203312436857">Figure 2</xref>).
<fig id="fig2-0961203312436857" position="float"><label>Figure 2</label><caption><p>Plots A and B show the differences between SLE patients and controls in serum levels of MMP-2 and neopterin. Statistical analyses were carried out by two-tailed non-parametric Mann–Whitney tests.</p></caption><graphic xlink:href="10.1177_0961203312436857-fig2.tif"/></fig>
<table-wrap id="table1-0961203312436857" position="float"><label>Table 1</label><caption><p>The demographic characteristics and distribution of risk factors in SLE patients and control subjects in a population from western Iran</p></caption>
<graphic alternate-form-of="table1-0961203312436857" xlink:href="10.1177_0961203312436857-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Parameter</th>
<th>SLE patients (<italic>n</italic> = 109)</th>
<th>Control subjects (<italic>n</italic> = 101)</th>
<th><italic>p</italic> values</th></tr></thead>
<tbody align="left">
<tr>
<td>Age (years)</td>
<td>35.6 ± 16.3</td>
<td>37.1 ± 11.5</td>
<td><sup>#</sup>NS</td></tr>
<tr>
<td>Sex (M/F)</td>
<td>19/90</td>
<td>22/82</td>
<td><sup>#</sup>NS</td></tr>
<tr>
<td>MMP-2 concentration (ng/mL)</td>
<td>295.1 ± 141.5</td>
<td>188.1 ± 28.6</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Neoptrin (nmol/L)</td>
<td>25.8 ± 38.1</td>
<td>6.5 ± 2.9</td>
<td>&lt;0.001</td></tr>
<tr>
<td>LDL-cholesterol (mg/dL)</td>
<td>119.7 ± 29.2</td>
<td>86.4 ± 37</td>
<td>&lt;0.001</td></tr>
<tr>
<td>HDL-cholesterol (mg/dL)</td>
<td>42.1 ± 21.1</td>
<td>42.7 ± 11</td>
<td>0.067<xref ref-type="table-fn" rid="table-fn1-0961203312436857">*</xref></td></tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>196 ± 37</td>
<td>188 ± 61</td>
<td>0.019<xref ref-type="table-fn" rid="table-fn1-0961203312436857">*</xref></td></tr>
<tr>
<td>Triacylglycerols (mg/dL)</td>
<td>179 ± 141</td>
<td>173 ± 117</td>
<td>0.76</td></tr>
<tr>
<td>SLE activity</td>
<td>21 ± 12.2</td>
<td>–</td>
<td>–</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312436857"><label>*</label><p><italic>p</italic> &gt; 0.05; <sup>#</sup>NS not significant.</p></fn>
<fn id="table-fn2-0961203312436857"><p>HDL: high-density lipoprotein; LDL: low-density lipoprotein; MMP: matrix metalloproteinase.</p></fn></table-wrap-foot>
</table-wrap></p>
<sec id="sec11-0961203312436857"><title>Functional MMP-2 promoter genotypes and alleles</title>
<sec id="sec12-0961203312436857"><title>Significant results</title>
<p>The allele and genotype frequencies are described in detail in <xref ref-type="table" rid="table2-0961203312436857">Table 2</xref>. Distribution of the functional MMP-2 promoter genotypes and alleles (as calculated using the actual allele number) were significantly different in SLE patients compared with control by the Hardy–Weinberg equilibrium (χ<sup>2 </sup>= 3.9, df = 1, <italic>p</italic> = 0.05 and χ<sup>2 </sup>= 4.9, df = 1, <italic>p</italic> = 0.028, respectively). However, no MMP-2 A/A genotype was detected in the control group (<xref ref-type="table" rid="table2-0961203312436857">Table 2</xref>). The age- and sex-adjusted odd ratio (OR) for SLE patients with homozygous and heterozygous genotypes (GA+AA) was 1.79 and OR for the presence of MMP-2 A allele was found to be 1.78 (1.1–3, p = 0.029) (<xref ref-type="table" rid="table3-0961203312436857">Table 3</xref>).
<table-wrap id="table2-0961203312436857" position="float"><label>Table 2</label><caption><p>The distribution of MMP-2 genotypes and alleles in SLE patients and control subjects</p></caption>
<graphic alternate-form-of="table2-0961203312436857" xlink:href="10.1177_0961203312436857-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>SLE patients (<italic>n</italic> = 109)</th>
<th>Control subjects (<italic>n</italic> = 101)</th></tr></thead>
<tbody align="left">
<tr>
<td>MMP-2 genotypes</td></tr>
<tr>
<td>G/G</td>
<td>66 (60.6%)</td>
<td>74 (73.3%)</td></tr>
<tr>
<td>G/A</td>
<td rowspan="2">39 (35.8%)</td>
<td>27 (26.7%)</td></tr>
<tr>
<td rowspan="2">A/A</td>
<td rowspan="2">0</td></tr>
<tr>
<td>4 (3.7%)</td></tr>
<tr>
<td/>
<td><xref ref-type="table-fn" rid="table-fn3-0961203312436857">*</xref>(χ<sup><xref ref-type="bibr" rid="bibr2-0961203312436857">2</xref></sup><sup> </sup>= 6.34, df = 2, p = 0.042)</td>
<td/></tr>
<tr>
<td>MMP-2 genotypes</td></tr>
<tr>
<td>G/G</td>
<td>66 (60.6%)</td>
<td>74 (73.3%)</td></tr>
<tr>
<td>G/A + A/A</td>
<td>43 (39.4%)</td>
<td>27 (26.7%)</td></tr>
<tr>
<td/>
<td><xref ref-type="table-fn" rid="table-fn3-0961203312436857">*</xref>(χ<sup>2 </sup>= 3.9, df = 1, <italic>p</italic> = 0.05)</td>
<td/></tr>
<tr>
<td>MMP-2 alleles</td></tr>
<tr>
<td>G</td>
<td>171 (78.4%)</td>
<td>175 (86.6%)</td></tr>
<tr>
<td>A</td>
<td>47 (21.6%)</td>
<td>27 (13.4%)</td></tr>
<tr>
<td/>
<td><xref ref-type="table-fn" rid="table-fn3-0961203312436857">*</xref>(χ<sup>2 </sup>= 4.9, df = 1, <italic>p</italic> = 0.028)</td>
<td/></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203312436857"><label>*</label><p>The distribution of alleles and genotypes frequencies of MMP-2 in SLE group compared with controls were made using χ<sup><xref ref-type="bibr" rid="bibr2-0961203312436857">2</xref></sup> test analysis.</p></fn>
<fn id="table-fn4-0961203312436857"><p>MMP: matrix metalloproteinase.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table3-0961203312436857" position="float"><label>Table 3</label><caption><p>Odds ratio of MMP-2 genotypes and alleles with respect to G/G or G in SLE patients after adjusted sex and age</p></caption>
<graphic alternate-form-of="table3-0961203312436857" xlink:href="10.1177_0961203312436857-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>SLE patients (<italic>n</italic> = 109)</th>
<th>Control subjects (<italic>n</italic> = 101)</th></tr></thead>
<tbody align="left">
<tr>
<td>MMP-2 genotypes</td>
<td rowspan="2">Reference group (<italic>n</italic> = 66)</td>
<td rowspan="4">Reference group (<italic>n</italic> = 74) <italic>n</italic> = 27</td></tr>
<tr>
<td rowspan="2">G/G</td></tr>
<tr>
<td rowspan="2">1.79 (1–3.2, <italic>p</italic> = 0.05, <italic>n</italic> = 43)</td></tr>
<tr>
<td>G/A + A/A</td></tr>
<tr>
<td>MMP-2 alleles</td>
<td rowspan="2">Reference group (<italic>n</italic> = 171)</td>
<td>Reference group</td></tr>
<tr>
<td>G</td>
<td rowspan="2">(<italic>n</italic> = 175)</td></tr>
<tr>
<td rowspan="2">A</td>
<td rowspan="2">1.78 (1.1–3, <italic>p</italic> = 0.029, <italic>n</italic> = 47)</td></tr>
<tr>
<td><italic>n</italic> = 27</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0961203312436857"><p>Odds ratios (OR) as estimates of relative risk for disease were calculated and 95% confidence intervals obtained by using χ<sup><xref ref-type="bibr" rid="bibr2-0961203312436857">2</xref></sup> regression binary logistic analysis.</p></fn>
<fn id="table-fn6-0961203312436857"><p>MMP: matrix metalloproteinase.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>As shown in <xref ref-type="table" rid="table4-0961203312436857">Table 4</xref>, the presence of the MMP-2 1575A genotypes had a significant effect on MMP-2, neopterin and LDL-C levels in both group of subjects. The SLE patients with the one and two copies of MMP-2 1575A allele (G/A + A/A) had significantly higher serum concentrations of MMP-2 (301 ± 166 ng/mL vs. 194 ± 35.5 ng/mL, <italic>p</italic> = 0.002), neoptrin (29.4 ± 39.4 nmol/L vs. 7.3 ± 4.6 nmol/L, <italic>p</italic> = 0.005) and LDL-C (120 ± 25.7 mg/dL vs. 87 ± 39.3 mg/dL, <italic>p</italic> &lt; 0.001), but lower HDL-C levels (39.6 ± 11 mg/dL vs. 45.9 ± 11.8 mg/dL, <italic>p</italic> = 0.031) than the corresponding subjects in the control group.
<table-wrap id="table4-0961203312436857" position="float"><label>Table 4</label><caption><p>Comparison of MMP-2 concentration, neoptrin, LDL-C, HDL-C, TC and TG levels between MMP-2 genotypes (G/G with G/A + A/A) in SLE patients with control subjects</p></caption>
<graphic alternate-form-of="table4-0961203312436857" xlink:href="10.1177_0961203312436857-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>SLE patients</th>
<th>Control subjects</th>
<th><italic>p</italic> values</th></tr>
<tr><th>G/G</th>
<th><italic>n</italic> = 66</th>
<th><italic>n</italic> = 74</th>
<th/></tr></thead>
<tbody align="left">
<tr>
<td>MMP-2 (ng/mL)</td>
<td>291 ± 122.7</td>
<td>186 ± 25.2</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Neoptrin (nmol/L)</td>
<td>23.3 ± 37.4</td>
<td>6.3 ± 2</td>
<td>&lt;0.001</td></tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>119 ± 31</td>
<td>86 ± 36</td>
<td>&lt;0.001</td></tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>44 ± 26.1</td>
<td>41.7 ± 10.6</td>
<td>0.5</td></tr>
<tr>
<td>TC (mg/dL)</td>
<td>192 ± 39</td>
<td>186 ± 53</td>
<td>0.45</td></tr>
<tr>
<td>TG (mg/dL)</td>
<td>181 ± 124</td>
<td>165 ± 117</td>
<td>0.48</td></tr>
<tr>
<td>G/A + A/A</td>
<td><italic>n</italic> = 43</td>
<td><italic>n</italic> = 27</td>
<td/></tr>
<tr>
<td>MMP-2 (ng/mL)</td>
<td>301 ± 166</td>
<td>194 ± 35.5</td>
<td>0.002</td></tr>
<tr>
<td>Neoptrin (nmo/l)</td>
<td>29.4 ± 39.4</td>
<td>7.3 ± 4.6</td>
<td>0.005</td></tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>120 ± 25.7</td>
<td>87 ± 39.3</td>
<td>&lt;0.001</td></tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>39.6 ± 11</td>
<td>45.9 ± 11.8</td>
<td>0.031</td></tr>
<tr>
<td>TC (mg/dL)</td>
<td>204 ± 31.5</td>
<td>191 ± 72</td>
<td>0.38</td></tr>
<tr>
<td>TG (mg/dL)</td>
<td>176 ± 164</td>
<td>196 ± 123</td>
<td>0.58</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0961203312436857"><p>A <italic>t</italic>-test was used to calculate the correlation values of serum MMP-2 concentration, neoptrin, LDL-C, HDL-C, TC and TG levels with MMP-2 polymorphisms between patients and controls.</p></fn>
<fn id="table-fn8-0961203312436857"><p>HDL: high-density lipoprotein; LDL: low-density lipoprotein; MMP: matrix metalloproteinase; TC: total serum cholesterol; TG: triacylglycerol.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>We compared serum MMP-2, neoptrin, lipid and lipoprotein levels among different groups of SLE patients i.e. without and with CVD, high blood pressure (BP) or lupus nephropathy (LN) (<xref ref-type="table" rid="table5-0961203312436857">Table 5</xref>). We only found differences between the levels of MMP-2, LDL-C and HDL-C in SLE patients with and without CVD. SLE patients with CVD had significantly higher serum levels of MMP-2 and LDL-C and lower HDL-C levels than those subjects without CVD (<xref ref-type="table" rid="table5-0961203312436857">Table 5</xref>).
<table-wrap id="table5-0961203312436857" position="float"><label>Table 5</label><caption><p>Comparison of MMP-2 concentration, neoptrin, LDL-C, HDL-C, TC and TG levels between SLE patients with and without CVD, raised blood pressure (BP) and lupus nephropathy (LN)</p></caption>
<graphic alternate-form-of="table5-0961203312436857" xlink:href="10.1177_0961203312436857-table5.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="3"/><th align="center" colspan="2">SLE patients<hr/></th>
<th align="center" colspan="2">SLE patients<hr/></th>
<th align="center" colspan="2">SLE patients<hr/></th></tr>
<tr><th>+CVD</th>
<th>−CVD</th>
<th>+BP</th>
<th>−BP</th>
<th>+LN</th>
<th>−LN</th></tr>
<tr><th><italic>n</italic> = 21</th>
<th><italic>n</italic> = 88</th>
<th><italic>n</italic> = 17</th>
<th><italic>n</italic> = 92</th>
<th><italic>n</italic> = 32</th>
<th><italic>n</italic> = 77</th></tr></thead>
<tbody align="left">
<tr>
<td rowspan="2">MMP-2 (ng/mL)</td>
<td>367±202</td>
<td>264±90.4</td>
<td>305±214</td>
<td>294±129</td>
<td>308±146</td>
<td>292±1414</td></tr>
<tr>
<td align="center" colspan="2"><italic>p</italic> = 0.001</td>
<td align="center" colspan="2"><italic>p</italic> = 0.86</td>
<td align="center" colspan="2"><italic>p</italic> = 0.7</td></tr>
<tr>
<td rowspan="2">Neoptrin (nmol/L)</td>
<td>44.1±52</td>
<td>17.7±26</td>
<td>38.7±46</td>
<td>23.5±36.3</td>
<td>39.1±44</td>
<td>22.8±36.4</td></tr>
<tr>
<td align="center" colspan="2"><italic>p</italic> = 0.001</td>
<td align="center" colspan="2"><italic>p</italic> = 0.15</td>
<td align="center" colspan="2"><italic>p</italic> = 0.091</td></tr>
<tr>
<td rowspan="2">LDL-C (mg/dL)</td>
<td>122.3±46.9</td>
<td>114.7±32</td>
<td>112±26.5</td>
<td>117.4±38.4</td>
<td>123.5±32.7</td>
<td>115.4±38</td></tr>
<tr>
<td align="center" colspan="2"><italic>p</italic> = 0.5</td>
<td align="center" colspan="2"><italic>p</italic> = 0.5</td>
<td align="center" colspan="2"><italic>p</italic> = 0.55</td></tr>
<tr>
<td rowspan="2">HDL-C (mg/dL)</td>
<td>40.5±13.8</td>
<td>45.9±32.6</td>
<td>43±21.3</td>
<td>42±21.3</td>
<td>39.6±17.1</td>
<td>42.6±21.9</td></tr>
<tr>
<td align="center" colspan="2"><italic>p</italic> = 0.26</td>
<td align="center" colspan="2"><italic>p</italic> = 0.87</td>
<td align="center" colspan="2"><italic>p</italic> = 0.61</td></tr>
<tr>
<td rowspan="2">TC (mg/dL)</td>
<td>210±78.5</td>
<td>190±51.4</td>
<td>198±41.1</td>
<td>196±63.8</td>
<td>211±47.4</td>
<td>192±63.4</td></tr>
<tr>
<td align="center" colspan="2"><italic>p</italic> = 0.15</td>
<td align="center" colspan="2"><italic>p</italic> = 0.89</td>
<td align="center" colspan="2"><italic>p</italic> = 0.25</td></tr>
<tr>
<td rowspan="2">TG (mg/dL)</td>
<td>213±185</td>
<td>163±115</td>
<td>175±134</td>
<td>179±143</td>
<td>221±136</td>
<td>170±141.6</td></tr>
<tr>
<td align="center" colspan="2"><italic>p</italic> = 0.12</td>
<td align="center" colspan="2"><italic>p</italic> = 0.93</td>
<td align="center" colspan="2"><italic>p</italic> = 0.2</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0961203312436857"><p>HDL: high-density lipoprotein; LDL: low-density lipoprotein; MMP: matrix metalloproteinase; TC: total serum cholesterol; TG: triacylglycerol.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Distribution and odds ratios of the functional MMP-2 promoter genotypes in SLE patients with and without CVD, BP and LN are shown in <xref ref-type="table" rid="table6-0961203312436857">Table 6</xref>. Distributions of the MMP-2 genotypes (χ<sup>2 </sup>= 5.4, df = 1, <italic>p</italic> = 0.02) was significantly different between SLE patients with and without CVD. The OR of MMP-2 (G/A + A/A) genotype was found to be 3.43 (1.16–10.2, <italic>p</italic> = 0.025) in SLE patients with CVD. Correlations between MMP-2 concentration with serum levels of neopterin, lipids, lipoproteins for SLE patients and SLE patients with CVD, LN and blood pressure are shown in <xref ref-type="table" rid="table7-0961203312436857">Table 7</xref>. Serum MMP-2 level was positively correlated with the levels of neopterin (<italic>r</italic> = 0.59, <italic>p</italic> &lt; 0.001), LDL-C (<italic>r</italic> = 0.21, <italic>p</italic> = 0.04) and TC (<italic>r</italic> = 0.26, <italic>p</italic> = 0.012), when the data from all the SLE patients were considered. In SLE patients with CVD, we observed a positive correlation between MMP-2 concentration with the levels of neopterin (<italic>r</italic> = 0.88, <italic>p</italic> &lt; 0.001) but a negative correlation between MMP-2 concentration and the level of HDL-C (<italic>r</italic> = −0.61, <italic>p</italic> = 0.035). However, except for neopterin (<italic>r</italic> = 0.59, <italic>p</italic> &lt; 0.001) in SLE patients with LN, we did not find any significant correlation between MMP-2 concentration and serum levels of neopterin, lipids and lipoproteins for SLE patients with LN and high blood pressure, In addition, there was no significant correlation between MMP-2 concentration and the serum levels of neopterin, lipids and lipoproteins in the control group and in SLE patients without CVD, LN and high blood pressure (data not shown).
<table-wrap id="table6-0961203312436857" position="float"><label>Table 6</label><caption><p>The distribution and odds ratios of MMP-2 G/A + A/A genotypes with respect to G/G genotypes in SLE patients with and without raised blood pressure, cardiovascular disease (CVD) and lupus nephropathy (LN)</p></caption>
<graphic alternate-form-of="table6-0961203312436857" xlink:href="10.1177_0961203312436857-table6.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2"/><th align="center" colspan="2">Blood pressure<hr/></th>
<th align="center" colspan="2">CVD<hr/></th>
<th align="center" colspan="2">LN<hr/></th></tr>
<tr><th>no</th>
<th>yes</th>
<th>no</th>
<th>yes</th>
<th>no</th>
<th>yes</th></tr></thead>
<tbody align="left">
<tr>
<td>MMP-2 genotype</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td>G/G</td>
<td>55 (62.5%)</td>
<td>11 (52.4%)</td>
<td>60 (65.2%)</td>
<td>6 (35.5%)</td>
<td>50 (64.9%)</td>
<td>16 (50%)</td></tr>
<tr>
<td>G/A + A/A</td>
<td>33 (37.5%)</td>
<td>10 (47.6%)</td>
<td>32 (34.8%)</td>
<td>11 (64.7%)</td>
<td>35 (35.1%)</td>
<td>16 (50%)</td></tr>
<tr>
<td rowspan="2"/>
<td align="center" colspan="2">*(χ<sup>2</sup> = 0.7, Df = 1, <italic>p</italic> = 0.39)</td>
<td align="center" colspan="2">*(χ<sup>2</sup> = 5.4, Df = 1, <italic>p</italic> = 0.02)</td>
<td align="center" colspan="2">*(χ<sup>2</sup> = 2.1, Df = 1, <italic>p</italic> = 0.14)</td></tr>
<tr>
<td align="center" colspan="2">OR = 1.52 (0.58–4, <italic>p</italic> = 0.4)</td>
<td align="center" colspan="2">OR = 3.43 (1.16–10.2, <italic>p</italic> = 0.025)</td>
<td align="center" colspan="2">OR = 1.85 (0.8–4.3, <italic>p</italic> = 0.15)</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn10-0961203312436857"><p>Odds ratios (OR) as estimates of relative risk for disease were calculated and 95% confidence intervals obtained by using χ<sup>2</sup> regression binary logistic analysis.</p></fn>
<fn id="table-fn11-0961203312436857"><p>MMP: matrix metalloproteinase.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table7-0961203312436857" position="float"><label>Table 7</label><caption><p>Correlation between MMP-2 concentration with neopterin, LDL-C, HDL-C, TC and TG in SLE patients and SLE patients with CVD, LN and blood pressure</p></caption>
<graphic alternate-form-of="table7-0961203312436857" xlink:href="10.1177_0961203312436857-table7.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>MMP-2 levels in SLE patients</th>
<th>MMP-2 levels in SLE patients with CVD</th>
<th>MMP-2 levels in SLE patients with LN</th>
<th>MMP-2 levels in SLE patients with raised blood pressure</th></tr></thead>
<tbody align="left">
<tr>
<td rowspan="2">Neoptrin (hg/mL)</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.59</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.88</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.65</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.7</td></tr>
<tr>
<td><italic>p</italic> &lt; 0.001</td>
<td><italic>p</italic> &lt; 0.001</td>
<td><italic>p</italic> = 0.001</td>
<td><italic>p</italic> = 0.004</td></tr>
<tr>
<td rowspan="2">LDL-C (mg/dL)</td>
<td><sup>#</sup><italic>r</italic> = 0.21</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.29</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.1</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.43</td></tr>
<tr>
<td><italic>p</italic> = 0.04</td>
<td><italic>p</italic> = 0.35</td>
<td><italic>p</italic> = 0.6</td>
<td><italic>p</italic> = 0.11</td></tr>
<tr>
<td rowspan="2">HDL-C (mg/dL)</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.08</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = − 0.61</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.01</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.04</td></tr>
<tr>
<td><italic>p</italic> = 0.48</td>
<td><italic>p</italic> = 0.035</td>
<td><italic>p</italic> = 0.97</td>
<td><italic>p</italic> = 0.89</td></tr>
<tr>
<td rowspan="2">TC (mg/dL)</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.26</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.49</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.35</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.36</td></tr>
<tr>
<td><italic>p</italic> = 0.012</td>
<td><italic>p</italic> = 0.1</td>
<td><italic>p = </italic>0.067</td>
<td><italic>p</italic> = 0.18</td></tr>
<tr>
<td rowspan="2">TG (mg/dL)</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.3</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.07</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.37</td>
<td><xref ref-type="table-fn" rid="table-fn12-0961203312436857">*</xref><italic>r</italic> = 0.37</td></tr>
<tr>
<td><italic>p</italic> = 0. 003</td>
<td><italic>p</italic> = 0.84</td>
<td><italic>p</italic> = 0.056</td>
<td><italic>p</italic> = 0.17</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn12-0961203312436857"><label>*</label><p>Pearson correlation coefficient; <sup>#</sup>Spearman correlation coefficient.</p></fn>
<fn id="table-fn13-0961203312436857"><p>HDL: high-density lipoprotein; LDL: low-density lipoprotein; MMP: matrix metalloproteinase; TC: total serum cholesterol; TG: triacylglycerol.</p></fn></table-wrap-foot>
</table-wrap></p></sec></sec></sec>
<sec id="sec13-0961203312436857" sec-type="discussion"><title>Discussion</title>
<p>In this study we have found a strong association between the MMP-2 functional polymorphism G1575A and the risk of SLE and the development of CVD in patients with SLE. We found that the MMP-2 1575A allele increases the risk of SLE by 1.78-fold and the presence of MMP-2 (G/A+A/A) genotype increases the risk of SLE and the development of CVD by 1.79 (<italic>p</italic> = 0.002) and 3.43-fold compared with MMP-2 G/G genotype, respectively.</p>
<p>The distribution of the MMP-2 genotypes in the SLE subjects was significantly different from that of the control group (χ<sup>2</sup> = 3.9, <italic>p</italic> = 0.05). The frequency of the MMP-2 G1575A allele was found to be higher in SLE subjects than in the control individuals (21.6 vs. 13.4%, <italic>p</italic> = 0.028). In addition, SLE patients with CVD had a significantly higher frequency of the MMP-2 (G/A+A/A) genotypes than those without CVD (<italic>p</italic> = 0.02).</p>
<p>Furthermore, as shown in <xref ref-type="table" rid="table4-0961203312436857">Table 4</xref>, SLE patients who carry one or two copies of MMP-2 1575 A allele(G/A+A/A) had significantly higher levels of MMP-2, neoptrin, LDL-C and lower serum levels of HDL-C than control groups carrying the corresponding MMP-2 allele. In addition, we found SLE patients with CVD had significantly higher serum concentrations of MMP-2 and neoptrin compared with SLE patients without CVD. This finding suggests that the MMP-2 1575A allele is a strong independent predictor for the development of CVD in SLE patients. These findings support the notion that the MMP-2 1575A allele increases the risk of SLE and the development of CVD in individuals. Carriers of the MMP-2 1575A allele have a high level of MMP-2 mRNA, protein and enzyme activity and stiffer large arteries.<sup><xref ref-type="bibr" rid="bibr8-0961203312436857">8</xref>,<xref ref-type="bibr" rid="bibr11-0961203312436857">11</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr19-0961203312436857">19</xref>,<xref ref-type="bibr" rid="bibr27-0961203312436857">27</xref></sup> Our data is further supported by other researchers’ observations that 1575G/A polymorphism in the promoter region of MMP-2 exerts an allelic effect on MMP-2 promoter strength, such that the A allelic promoter has a higher transcriptional activity than the G allelic promoter, which is likely to be attributed to binding a transcriptional repressor to the G allele.<sup><xref ref-type="bibr" rid="bibr8-0961203312436857">8</xref>,<xref ref-type="bibr" rid="bibr13-0961203312436857">13</xref>,<xref ref-type="bibr" rid="bibr25-0961203312436857">25</xref>,<xref ref-type="bibr" rid="bibr28-0961203312436857">28</xref></sup></p>
<p>Although the underlying cause of SLE is not fully known, recent reports indicate that proinflammatory cytokines, especially tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1), play an important role in the pathogenesis of SLE. The latter cytokine is shown to directly induce MMPs in synovial fibroblasts<sup><xref ref-type="bibr" rid="bibr29-0961203312436857">29</xref></sup> and monocytes.<sup><xref ref-type="bibr" rid="bibr30-0961203312436857">30</xref></sup> MMPs secreted by T cells, and macrophages in turn facilitate secretion of TNF-α, by cleavage of its membrane-bound form.<sup><xref ref-type="bibr" rid="bibr31-0961203312436857">31</xref></sup> Thus, these data in conjunction with our results suggest that the mutual regulatory effects of pro inflammatory cytokines and MMP play an important role in pathogenesis of SLE.</p>
<p>The present study shows that the role of the MMP-2 1575A allele as a risk factor for SLE and the development of CVD in SLE patients is not only due to its association with a high serum MMP-2 concentration but also by its association with a high level of the atherogenic LDL-C, TC and inflammatory factor neopterin. Atherosclerosis is not only a disease of lipid accumulation, but also a chronic inflammatory process,<sup><xref ref-type="bibr" rid="bibr8-0961203312436857">8</xref>,<xref ref-type="bibr" rid="bibr32-0961203312436857">32</xref></sup> which is apparently initiated in response to arterial endothelial injury. This allows increased permeability to lipid, monocytes and lipid-laden macrophages. In vitro studies have shown that oxidized lipoproteins stimulate transformation of macrophages into foam cells that produce MMPs.<sup><xref ref-type="bibr" rid="bibr3-0961203312436857">3</xref>,<xref ref-type="bibr" rid="bibr4-0961203312436857">4</xref></sup> The MMP-2 secreted from macrophages apparently helps medial smooth muscle to migrate into the intima by degrading extracellular matrix.<sup><xref ref-type="bibr" rid="bibr8-0961203312436857">8</xref>,<xref ref-type="bibr" rid="bibr32-0961203312436857">32</xref></sup> Guo et al. demonstrated, rosuvastatin a HMG-CoA reductase inhibitor used to reduce the amount of cholesterol, oxLDL, LDL-C and TGs, inhibits the expression of MMP-2/−9 and limits the progression of atherosclerosis in low-density lipoprotein receptor (LDLR) deficient mice. The decreased MMP levels are in agreement with the reduction in oxidized lipids and indicate a strong relationship between expression of MMPs by inflammatory cells and lipoprotein levels in the development of atherosclerosis.<sup><xref ref-type="bibr" rid="bibr33-0961203312436857">33</xref></sup> Whether MMP expression by macrophage derived foam cells leads to production of LDL-C and TC in SLE patients or vice versa remains to be determined.</p></sec>
<sec id="sec14-0961203312436857" sec-type="conclusions"><title>Conclusion</title>
<p>In the present study, we demonstrated for the first time that the genotype distribution and allele frequencies of the MMP-2 G1575 to A polymorphism are significantly different between subjects with and without SLE. The carriers of MMP-2 G1575 to A allele have distinctly elevated serum levels of MMP-2 and neopterin and lipid profiles, suggesting that these individuals may be more susceptible to cardiovascular disease and myocardial infarction. This study also indicated that carriers of the MMP-2 A(G/A+AA) allele had 3.43-fold higher risk of developing CVD than those with the GG homozygote.</p></sec>
</body>
<back><ack>
<title>Acknowledgements</title>
<p>This work was performed in partial fulfillment of requirements for an MSc degree in Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran (Fariborz Bahrehmand). All authors contributed equally to this study.</p></ack>
<sec id="sec15-0961203312436857"><title>Funding</title>
<p>This work was supported by the Kermanshah University of Medical Sciences, Kermanshah, Iran (grant number 86049).</p></sec>
<sec id="sec16-0961203312436857"><title>Conflict of interest</title>
<p>We declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.</p></sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312436857"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacobsen</surname><given-names>S</given-names></name><name><surname>Petersen</surname><given-names>J</given-names></name><name><surname>Ullman</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus</article-title>. <source>Scand J Rheumatol</source> <year>1999</year>; <volume>28</volume>: <fpage>75</fpage>–<lpage>80</lpage>.</citation></ref>
<ref id="bibr2-0961203312436857"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bellomip</surname><given-names>V</given-names></name><name><surname>Spindler</surname><given-names>A</given-names></name><name><surname>Lucero</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Systemic lupus erythematosus: mortality and survival in Argentina</article-title>. <source><italic>A multicenter study</italic>. Lupus</source> <year>2000</year>; <volume>9</volume>: <fpage>377</fpage>–<lpage>381</lpage>.</citation></ref>
<ref id="bibr3-0961203312436857"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>MM</given-names></name></person-group>. <article-title>Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1999</year>; <volume>42</volume>: <fpage>338</fpage>–<lpage>346</lpage>.</citation></ref>
<ref id="bibr4-0961203312436857"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Plazak</surname><given-names>W</given-names></name><name><surname>Gryga</surname><given-names>K</given-names></name><name><surname>Dziedzic</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study</article-title>. <source>Arthritis Res Ther</source> <year>2011</year>; <volume>13</volume>: <fpage>R117</fpage>–<lpage>R117</lpage>.</citation></ref>
<ref id="bibr5-0961203312436857"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wallberg-Jonsson</surname><given-names>S</given-names></name><name><surname>Ohman</surname><given-names>ML</given-names></name><name><surname>Dahlqvist</surname><given-names>SR</given-names></name></person-group>. <article-title>Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden</article-title>. <source>J Rheumatol</source> <year>1997</year>; <volume>24</volume>: <fpage>445</fpage>–<lpage>451</lpage>.</citation></ref>
<ref id="bibr6-0961203312436857"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farber-Elman</surname><given-names>A</given-names></name><name><surname>Sthoeger</surname><given-names>Z</given-names></name><name><surname>Tcherniack</surname><given-names>A</given-names></name><name><surname>Dayan</surname><given-names>M</given-names></name><name><surname>Mozes</surname><given-names>E</given-names></name></person-group>. <article-title>Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus</article-title>. <source>Clin Exp Immunol</source> <year>2002</year>; <volume>127</volume>: <fpage>393</fpage>–<lpage>398</lpage>.</citation></ref>
<ref id="bibr7-0961203312436857"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kvalvik</surname><given-names>AG</given-names></name><name><surname>Jones</surname><given-names>MA</given-names></name><name><surname>Symmons</surname><given-names>DP</given-names></name></person-group>. <article-title>Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992</article-title>. <source>Scand J Rheumatol</source> <year>2000</year>; <volume>29</volume>: <fpage>29</fpage>–<lpage>37</lpage>.</citation></ref>
<ref id="bibr8-0961203312436857"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Herrmann</surname><given-names>SM</given-names></name><etal/></person-group>. <article-title>Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis</article-title>. <source>Circulation</source> <year>1999</year>; <volume>99</volume>: <fpage>1788</fpage>–<lpage>1794</lpage>.</citation></ref>
<ref id="bibr9-0961203312436857"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibbons</surname><given-names>GH</given-names></name><name><surname>Dzau</surname><given-names>VJ</given-names></name></person-group>. <article-title>The emerging concept of vascular remodelling</article-title>. <source>N Engl J Med</source> <year>1994</year>; <volume>330</volume>: <fpage>1431</fpage>–<lpage>1438</lpage>.</citation></ref>
<ref id="bibr10-0961203312436857"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galis</surname><given-names>ZS</given-names></name><name><surname>Khatri</surname><given-names>JJ</given-names></name></person-group>. <article-title>Matrix metalloproteinases in vascular remodeling and atherogenesis. The good, the bad, and the ugly</article-title>. <source>Circ Res</source> <year>2002</year>; <volume>90</volume>: <fpage>251</fpage>–<lpage>262</lpage>.</citation></ref>
<ref id="bibr11-0961203312436857"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saedi</surname><given-names>M</given-names></name><name><surname>Vaisi-Raygani</surname><given-names>A</given-names></name><name><surname>Khaghani</surname><given-names>S</given-names></name></person-group>. <article-title>Matrix metalloproteinas-9 functional promoter polymorphism 1562C&gt;T increased risk of early-onset coronary artery disease</article-title>. <source>Mol Biol Rep</source> <year>2012</year>; <volume>39</volume>: <fpage>555</fpage>–<lpage>562</lpage>.</citation></ref>
<ref id="bibr12-0961203312436857"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gai</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>MMP-2 and TIMP-2 gene polymorphisms and susceptibility to atrial fibrillation in Chinese Han patients with hypertensive heart disease</article-title>. <source>Clinica Chimica Acta</source> <year>2010</year>; <volume>411</volume>: <fpage>719</fpage>–<lpage>724</lpage>.</citation></ref>
<ref id="bibr13-0961203312436857"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Füth</surname><given-names>R</given-names></name><name><surname>Dinh</surname><given-names>W</given-names></name><name><surname>Nickl</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Soluble P-selectin and matrix metalloproteinase 2 levels are elevated in patients with diastolic dysfunction independent of glucose metabolism disorder or coronary artery disease</article-title>. <source>Exp Clin Cardiol</source> <year>2009</year>; <volume>14</volume>: <fpage>e76</fpage>–<lpage>e79</lpage>.</citation></ref>
<ref id="bibr14-0961203312436857"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>YH</given-names></name><name><surname>Lin</surname><given-names>IL</given-names></name><name><surname>Tsay</surname><given-names>GJ</given-names></name><etal/></person-group>. <article-title>Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus</article-title>. <source>Clin Biochem</source> <year>2008</year>; <volume>41</volume>: <fpage>955</fpage>–<lpage>959</lpage>.</citation></ref>
<ref id="bibr15-0961203312436857"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Lopez</surname><given-names>J</given-names></name><name><surname>Perez-Pampin</surname><given-names>E</given-names></name><name><surname>Gomez-Reino</surname><given-names>JJ</given-names></name><name><surname>Gonzalez</surname><given-names>A</given-names></name></person-group>. <article-title>Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study</article-title>. <source>Arthritis Res Ther</source> <year>2006</year>; <volume>8</volume>: <fpage>R1</fpage>–<lpage>R1</lpage>.</citation></ref>
<ref id="bibr16-0961203312436857"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vasku</surname><given-names>A</given-names></name><name><surname>Goldbergova</surname><given-names>M</given-names></name><name><surname>Holla</surname><given-names>II</given-names></name><name><surname>Siskova</surname><given-names>L</given-names></name><name><surname>Groch</surname><given-names>L</given-names></name></person-group>. <article-title>A haplotype constituted of four MMP-2 promoter polymorphisms (y1575GyA, y1306CyT, y790TyG an dy735CyT) is associated with coronary triple-vessel disease</article-title>. <source>Matrix Biology</source> <year>2004</year>; <volume>22</volume>: <fpage>585</fpage>–<lpage>591</lpage>.</citation></ref>
<ref id="bibr17-0961203312436857"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alp</surname><given-names>E</given-names></name><name><surname>Menevse</surname><given-names>S</given-names></name><name><surname>Tulmac</surname><given-names>M</given-names></name><name><surname>Yilmaz</surname><given-names>A</given-names></name><name><surname>Yalcin</surname><given-names>R</given-names></name><name><surname>Cengel</surname><given-names>A</given-names></name></person-group>. <article-title>The role of matrix metalloproteinase-2 promoter polymorphisms in coronary artery disease and myocardial infarction</article-title>. <source>Genet Test Mol Biomarkers</source> <year>2011</year>; <volume>15</volume>: <fpage>193</fpage>–<lpage>202</lpage>.</citation></ref>
<ref id="bibr18-0961203312436857"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pasterkamp</surname><given-names>G</given-names></name><name><surname>Schoneveld</surname><given-names>AH</given-names></name><name><surname>Hijnen</surname><given-names>DJ</given-names></name></person-group>. <article-title>Atherosclerotic arterial remodeling and the localization of macrophages and matrix metaloproteases-1, -2 and -9 in the human coronary artery</article-title>. <source>Atherosclerosis</source> <year>2000</year>; <volume>150</volume>: <fpage>245</fpage>–<lpage>253</lpage>.</citation></ref>
<ref id="bibr19-0961203312436857"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noji</surname><given-names>Y</given-names></name><name><surname>Kajinami</surname><given-names>K</given-names></name><name><surname>Kawashiri</surname><given-names>MA</given-names></name></person-group>. <article-title>Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis</article-title>. <source>Clin Chem Lab Med</source> <year>2001</year>; <volume>39</volume>: <fpage>380</fpage>–<lpage>384</lpage>.</citation></ref>
<ref id="bibr20-0961203312436857"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hojo</surname><given-names>Y</given-names></name><name><surname>Ikeda</surname><given-names>U</given-names></name><name><surname>Ueno</surname><given-names>S</given-names></name><name><surname>Arakawa</surname><given-names>H</given-names></name><name><surname>Shoimada</surname><given-names>K</given-names></name></person-group>. <article-title>Expression of matrix metalloproteinases in patients with acute myocardial infarction</article-title>. <source>Jap Circ J</source> <year>2001</year>; <volume>65</volume>: <fpage>71</fpage>–<lpage>75</lpage>.</citation></ref>
<ref id="bibr21-0961203312436857"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group>. <article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>1725</fpage>–<lpage>1725</lpage>.</citation></ref>
<ref id="bibr22-0961203312436857"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>D</given-names></name><name><surname>Ginzler</surname><given-names>E</given-names></name><name><surname>Goldsmith</surname><given-names>C</given-names></name><name><surname>Fortin</surname><given-names>P</given-names></name><name><surname>Liang</surname><given-names>M</given-names></name><name><surname>Urowitz</surname><given-names>M</given-names></name></person-group>. <article-title>The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1996</year>; <volume>39</volume>: <fpage>363</fpage>–<lpage>363</lpage>.</citation></ref>
<ref id="bibr23-0961203312436857"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carru</surname><given-names>C</given-names></name><name><surname>Zinellu</surname><given-names>A</given-names></name><name><surname>Sotgia</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>A new HPLC method for serum neopterin measurement and relationships with plasma thiols levels in healthy subjects</article-title>. <source>Biomed Chromatogr</source> <year>2004</year>; <volume>18</volume>: <fpage>360</fpage>–<lpage>366</lpage>.</citation></ref>
<ref id="bibr24-0961203312436857"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elizabeth</surname><given-names>A</given-names></name><name><surname>Flavall</surname><given-names>A</given-names></name><name><surname>Elizabeth</surname><given-names>M</given-names></name></person-group>. <article-title>Dissociation of neopterin and 7,8-dihydroneopterin from plasma components before HPLC analysis</article-title>. <source>J Chromatography B</source> <year>2008</year>; <volume>863</volume>: <fpage>167</fpage>–<lpage>171</lpage>.</citation></ref>
<ref id="bibr25-0961203312436857"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vaisi-Raygani</surname><given-names>A</given-names></name><name><surname>Rahimi</surname><given-names>Z</given-names></name><name><surname>Tavilani</surname><given-names>H</given-names></name><name><surname>Pourmotaabed</surname><given-names>T</given-names></name></person-group>. <article-title>Butyrylcholinesterase K variant and the APOE-epsilon4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients</article-title>. <source>Mol Biol Rep</source> <year>2010</year>; <volume>37</volume>: <fpage>2083</fpage>–<lpage>2091</lpage>.</citation></ref>
<ref id="bibr26-0961203312436857"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harendza</surname><given-names>S</given-names></name><name><surname>Lovett</surname><given-names>DH</given-names></name><name><surname>Panzer</surname><given-names>U</given-names></name><name><surname>Lukacs</surname><given-names>Z</given-names></name><name><surname>Ku</surname><given-names>P</given-names></name><name><surname>Stahlrf</surname><given-names>K</given-names></name></person-group>. <article-title>Linked Common Polymorphisms in the Gelatinase A Promoter Are Associated with Diminished Transcriptional Response to Estrogen and Genetic Fitness</article-title>. <source>J Biol Chem</source> <year>2003</year>; <volume>2789</volume>: <fpage>20490</fpage>–<lpage>20499</lpage>.</citation></ref>
<ref id="bibr27-0961203312436857"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>IM</given-names></name><name><surname>Swingler</surname><given-names>TE</given-names></name><name><surname>Sampieri</surname><given-names>CL</given-names></name><name><surname>Edwards</surname><given-names>DR</given-names></name></person-group>. <article-title>The regulation of matrix metalloproteinases and their inhibitors</article-title>. <source>Int J Biochem Cell Biol</source> <year>2008</year>; <volume>40</volume>: <fpage>1362</fpage>–<lpage>1378</lpage>.</citation></ref>
<ref id="bibr28-0961203312436857"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>SJ</given-names></name><name><surname>Greaves</surname><given-names>DR</given-names></name><name><surname>Watkins</surname><given-names>H</given-names></name></person-group>. <article-title>Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation</article-title>. <source>J Biol Chem</source> <year>2001</year>; <volume>276</volume>: <fpage>7549</fpage>–<lpage>7558</lpage>.</citation></ref>
<ref id="bibr29-0961203312436857"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>MacNaul</surname><given-names>KL</given-names></name><name><surname>Chartrain</surname><given-names>N</given-names></name><name><surname>Lark</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinase-1 in rheumatoid synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression</article-title>. <source>J Biol Chem</source> <year>1990</year>; <volume>265</volume>: <fpage>17238</fpage>–<lpage>17245</lpage>.</citation></ref>
<ref id="bibr30-0961203312436857"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>McCluskey</surname><given-names>K</given-names></name><name><surname>Fujii</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-α, granulocyte-macrophage CSF, and IL-1β through prostaglandin-dependent and-independent mechanisms</article-title>. <source>J Immunol</source> <year>1998</year>; <volume>161</volume>: <fpage>3071</fpage>–<lpage>3076</lpage>.</citation></ref>
<ref id="bibr31-0961203312436857"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goetzl</surname><given-names>EJ</given-names></name><name><surname>Banda</surname><given-names>MJ</given-names></name><name><surname>Leppert</surname><given-names>D</given-names></name></person-group>. <article-title>Matrix metalloproteinases in immunity</article-title>. <source>J Immunol</source> <year>1996</year>; <volume>156</volume>: <fpage>1</fpage>–<lpage>4</lpage>.</citation></ref>
<ref id="bibr32-0961203312436857"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kieffer</surname><given-names>P</given-names></name><name><surname>Giummelly</surname><given-names>P</given-names></name><name><surname>Schjoth</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Activation of metalloproteinase-2, loss of matrix scleroprotein content and coronary artery calcification</article-title>. <source>Atherosclerosis</source> <year>2001</year>; <volume>157</volume>: <fpage>251</fpage>–<lpage>254</lpage>.</citation></ref>
<ref id="bibr33-0961203312436857"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Chi</surname><given-names>G</given-names></name></person-group>. <article-title>Rosuvastatin Inhibits MMP-2 Expression and Limits the Progression of Atherosclerosis in LDLR-deficient Mice</article-title>. <source>Arch Med Res</source> <year>2009</year>; <volume>40</volume>: <fpage>345</fpage>–<lpage>351</lpage>.</citation></ref>
</ref-list>
</back>
</article>